Article
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Cancer - 1 Aug 2014
Zhao Mingchuan, Zhang Yishi, Cai Weijing, Li Jiayu, Zhou Fei, Cheng Ningning, Ren Ruixin, Zhao Chao, Li Xuefei, Ren Shengxiang, Zhou Caicun, Hirsch Fred R
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have EGFR mutations. Recent studies have indicated that some patients with positive mutations were refractory to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
